These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 1517380)

  • 41. Hyperoxaluria is not a cause of nephrocalcinosis in phosphate-treated patients with hereditary hypophosphatemic rickets.
    Tieder M; Blonder J; Strauss S; Shaked U; Maor J; Gabizon D; Manor H; Sela BA
    Nephron; 1993; 64(4):526-31. PubMed ID: 8396209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Growth hormone therapy in hypophosphatemic rickets.
    Wilson DM; Lee PD; Morris AH; Reiter EO; Gertner JM; Marcus R; Quarmby VE; Rosenfeld RG
    Am J Dis Child; 1991 Oct; 145(10):1165-70. PubMed ID: 1928011
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcitriol treatment in vitamin D-dependent and vitamin D-resistant rickets.
    Glorieux FH
    Metabolism; 1990 Apr; 39(4 Suppl 1):10-2. PubMed ID: 2157942
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of GH replacement therapy in two male siblings with combined X-linked hypophosphatemia and partial GH deficiency.
    Schütt SM; Schumacher M; Holterhus PM; Felgenhauer S; Hiort O
    Eur J Endocrinol; 2003 Oct; 149(4):317-21. PubMed ID: 14514346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nephrocalcinosis, hyperparathyroidism, and renal failure in familial hypophosphatemic rickets.
    Alon U; Lovell HB; Donaldson DL
    Clin Pediatr (Phila); 1992 Mar; 31(3):180-3. PubMed ID: 1547591
    [No Abstract]   [Full Text] [Related]  

  • 46. Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets.
    Mäkitie O; Kooh SW; Sochett E
    Clin Endocrinol (Oxf); 2003 Feb; 58(2):163-8. PubMed ID: 12580931
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased renal catabolism of 1,25-dihydroxyvitamin D3 in murine X-linked hypophosphatemic rickets.
    Tenenhouse HS; Yip A; Jones G
    J Clin Invest; 1988 Feb; 81(2):461-5. PubMed ID: 3339128
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful treatment of genetically hypophosphatemic mice by 1 alpha-hydroxyvitamin D3 but not 1,25-dihydroxyvitamin D3.
    Beamer WG; Wilson MC; DeLuca HF
    Endocrinology; 1980 Jun; 106(6):1949-55. PubMed ID: 6892799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia.
    Seikaly MG; Brown R; Baum M
    Pediatrics; 1997 Nov; 100(5):879-84. PubMed ID: 9346990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII).
    al-Aqeel A; Ozand P; Sobki S; Sewairi W; Marx S
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):229-37. PubMed ID: 8396512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 24R,25-dihydroxyvitamin D3 promotes bone formation without causing excessive resorption in hypophosphatemic mice.
    Ono T; Tanaka H; Yamate T; Nagai Y; Nakamura T; Seino Y
    Endocrinology; 1996 Jun; 137(6):2633-7. PubMed ID: 8641218
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intramyocellular phosphate metabolism in X-linked hypophosphatemic rickets.
    Clarke GD; Kainer G; Conway WF; Chan JC
    J Pediatr; 1990 Feb; 116(2):288-92. PubMed ID: 2299505
    [No Abstract]   [Full Text] [Related]  

  • 53. Nephrocalcinosis and its relationship to treatment of hereditary rickets.
    Goodyer PR; Kronick JB; Jequier S; Reade TM; Scriver CR
    J Pediatr; 1987 Nov; 111(5):700-4. PubMed ID: 2822887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response of rachitic rat bones to 1,25-dihydroxyvitamin D3: biphasic effects on mineralization and lack of effect on bone resorption.
    Gallagher JA; Beneton M; Harvey L; Lawson DE
    Endocrinology; 1986 Oct; 119(4):1603-9. PubMed ID: 3757903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Vitamin-D-resistant hypophosphatemic rickets].
    Velásquez-Jones L; Dorantes-Alvarez L; Ajuria ML
    Bol Med Hosp Infant Mex; 1984 Oct; 41(10):561-8. PubMed ID: 6095879
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1 alpha-hydroxyvitamin D3.
    Rasmussen H; Pechet M; Anast C; Mazur A; Gertner J; Broadus AE
    J Pediatr; 1981 Jul; 99(1):16-25. PubMed ID: 6265614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia.
    Carey DE; Drezner MK; Hamdan JA; Mange M; Ahmad MS; Mubarak S; Nyhan WL
    J Pediatr; 1986 Dec; 109(6):994-1000. PubMed ID: 3023599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tertiary hyperparathyroidism in X-linked hypophosphatemic rickets.
    Wu CJ; Song YM; Sheu WH
    Intern Med; 2000 Jun; 39(6):468-71. PubMed ID: 10852165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rickets and alopecia with resistance to 1,25-dihydroxyvitamin D: two different clinical courses with two different cellular defects.
    Balsan S; Garabedian M; Liberman UA; Eil C; Bourdeau A; Guillozo H; Grimberg R; Le Deunff MJ; Lieberherr M; Guimbaud P; Broyer M; Marx SJ
    J Clin Endocrinol Metab; 1983 Oct; 57(4):803-11. PubMed ID: 6309886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.